Ann: ATL1102 Early Access Program for Patients with MS, page-20

My post from last week was extracted from the company update on 9/12/14

"With respect to ATL1102 for MS, the Company recently received a positive response from the US Food and Drug Administration following the agency’s Pre-IND assessment of the development strategy for ATL1102, including plans for a Phase IIb trial in MS patients (ASX: ATL1102 for MS – FDA Response to Phase IIb Study Plans, 24 October 2014). Destum have similarly been engaged to help ANP find a suitable development partner for ATL1102. Both ANP and Destum are in ongoing dialogue with potential pharmaceutical company partners. The process of attracting a suitable partner for ATL1102 is anticipated to take up to six months"

The six months is up on the 9 of June.... other projected timelines have been on track so yes i am expecting something soon. Mark had said to others that two weeks either way is not significant so anytime in June or before. This is the one we have been waiting for!!!